A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer

Cancer Ovaries Clinical Trial

Official title:

A Phase 1b Study of OMP-305B83 Plus Weekly Paclitaxel in Subjects With Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03030287
• Other study ID #: B83-002
• Status: Completed
• Phase: Phase 1
• Start date: December 2016
• Est. completion date: April 2020

Study information

• Verified date: September 2020
• Source: Mereo BioPharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to test the efficacy and safety of an experimental drug, OMP-305B83, when given in combination with paclitaxel. OMP-305B83 is a humanized monoclonal antibody and was developed to target cancer stem cells. Based on preclinical studies, it is believed that OMP-305B83 may block the growth of cancer stem cells and may also impair the productive growth of new blood vessels, which tumors need to grow and spread.

Description:

This is an open-label, Phase 1b dose escalation and expansion study of OMP-305B83 plus paclitaxel designed to evaluate the safety, efficacy and pharmacokinetics of OMP-305B83 in combination with paclitaxel in patients with platinum resistant ovarian, primary peritoneal or fallopian tube cancer. This study consists of a screening period, a treatment period and a post-treatment follow up period in which patients will be followed for survival for approximately 12 months. Patients will be enrolled in two stages: a dose-escalation stage and an expansion phase.

Approximately 30 patients will be enrolled in this study at approximately 5 study centers in the United States (U.S)..

Recruitment information / eligibility

• Status: Completed
• Enrollment: 44
• Est. completion date: April 2020
• Est. primary completion date: April 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

1. Platinum resistant Grade 2 or 3 ovarian, primary peritoneal or fallopian tube cancer

2. Measureable disease per response evaluation criteria (RECIST) v1.1

3. Prior bevacizumab

4. Age > or = 21 years

5. Adequate organ and marrow function

6. For women of childbearing potential and men with partners of childbearing potential, agreement (by patient and/or partner) to use two effective forms of contraception from study entry through at least 6 months after the termination visit.

7. Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

1. Treatment with any anti-cancer therapy, including radiotherapy, chemotherapy, biologic therapy. Prior therapy with weekly paclitaxel for recurrent disease, unless administered more than 2 years prior to enrollment, unless part of an upfront treatment strategy.

2. History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, clinical signs or symptoms of gastrointestinaI obstruction or other known clinically signification gastrointestinal disease.

3. Subjects with brain metastases

4. Subjects with leptomeningial disease or neoplasms in the last 5 years

5. Blood pressure >140/80

6. Significant intercurrent illness that will limit the patient's ability to participate in the study

7. Subjects with known metastases that are currently involving the lumen of the gastrointestinal tract.

8. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment, or anticipation of need for major surgical procedure during the course of the study

9. Pregnant or nursing women

10. New York Heart Association Classification II, III, or IV

11. Inability to comply with study and follow up procedure

Related Conditions & MeSH terms

• Cancer Ovaries
• Cancer Peritoneal
• Cancer, Fallopian Tube
• Fallopian Tube Neoplasms

Intervention

Drug:
• OMP-305B83
intravenous (in the vein) infusion
• Paclitaxel
administered intravenously

Locations

Country	Name	City	State
United States	University of Colorado, Anschutz Medical Campus	Aurora	Colorado
United States	Levine Cancer Institute	Charlotte	North Carolina
United States	The University of Texas, MD Anderson Cancer Center	Houston	Texas
United States	Tennessee Oncology, PLLC	Nashville	Tennessee
United States	Stephenson Cancer Center	Oklahoma City	Oklahoma
United States	The University of Pennsylvania Health System	Philadelphia	Pennsylvania
United States	H. Lee Moffitt Cancer Center & Research Institute, Inc. (Moffitt Cancer Center)	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
OncoMed Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of dose limiting toxicities (DLT)	The maximum tolerated dose (MTD) or maximum administered dose (MAD) will be determined in subjects treated with OMP-305B83 in combination with Paclitaxel	Subjects will be treated and observed for DLT through the end of the first cycle (Days 0-28).
Secondary	Safety of OMP-30B583 in combination with Paclitaxel will be assessed by adverse event monitoring, physical exams, vital signs, clinical laboratory testing, ECGs, echocardiograms, anti-OMP-305B83 testing, and subject interview on an ongoing basis.		Through study completion, an average of 6 months
Secondary	To assess Immunogenicity (in terms of formation of anti-drug antibod(ies) against OMP-305B83 in percentage of subjects) of OMP-305B83 in combination with Paclitaxel		Through study completion, an average of 6 months
Secondary	Response Rate assessed by RECIST criteria 1.1		At 56 day intervals while on treatment, through study completion, an average of 6 months
Secondary	Response Rate assessed by CA-125 criteria		At 28 day intervals while on treatment, through study completion, an average of 6 months
Secondary	Progression Free Survival		Up to 5 years